Publication of study data

RNS REACH

18 November 2014

Silence Therapeutics plc

Publication of first-in-human study data on use of Atu027 RNAi in advanced solid tumours

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, announces that study data on the first-in-human trial of the use of its Atu027 RNAi (RNA interference) technology in patients with advanced solid tumours has today been pre-published online by the Journal of Clinical Oncology, the peer reviewed journal and official publication of the American Society of Clinical Oncology (ASCO).

The study found that Atu027 was well tolerated and safe in patients with advanced solid tumours. Disease stabilisation was also achieved in 41% of patients for at least eight weeks after treatment.

The article is entitled 'First-In-Human Phase-I study of the liposomal RNAi therapeutic Atu027 in patients with advanced solid tumours'. The study was carried out alongside collaborators at the Department of Hematology and Oncology at the Marienhospital Herne, University of Bochum in Germany led by Dr Dirk Strumberg. The article can be found at www.jco.org.

The final analysis of this study was also presented in a verbal update session at the ASCO Annual Meeting in June 2013.

Enquiries

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNA interference (RNAi) or 'gene silencing' platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.

Silence is one of only a handful of listed companies globally which has human validated RNA delivery technology and RNAi platform technology. Its platform is one of the safest and most widely tested, with over 400 patients dosed. Silence's RNAi platform has been used in three Phase 2 clinical trials, two of which are awaiting results. It also has a robust IP estate protecting its proprietary technology.